definiens: shall mean all disco very, research and development activities to be performed under this Agreement by or on behalf of ( a ) Regeneron, including IO Target identification, d iscovery and validation, IND Preparation and IND filing for IO Discovery Program Antibodies, and IO Licensed Pr oducts [ * * * ] and clinical trials as part of POC Developmen t for such IO Antibodies, or ( b ) either Party, with respect to [COMPANY] Funded Trials . The IO Discovery Program prev iously included ( i ) discovery research activities d irected at IO Target identification, validation, and selection, and ( ii ) IO Antibody discovery, identification an d selection ; and from and after the A&R Agreement Effective Date shall continue to include ( iii ) IO Discovery Progr am Antibody characterization and pharmacological asses sment ( if applicable ) and selection, ( iv ) the produ ction of IO Discovery Program Antibodies for preclinical exp eriments and clinical studies, ( v ) IND Preparation and the filing of INDs, ( vi ) the conduct of non - clinical an d clinical tests and studies to achieve POC, includ ing clinical translational studies, Phase I Clinical Trials and Phase II Clinical Trials, and ( vii ) the development of companion diagnostics for use with IO Discovery Program Antib odies . For clarity, the IO Discovery Program shall include any activities conducted pursuant to Section 5.4 or Section 5.5 . Notwithstanding the foregoing, it is understood that the activities described in clauses ( i ) and ( i i ) above have been completed with respect to the IO Discovery Program Antibodies as of the A&R Agreement Effectiv e Date, and no additional activities described in c lauses ( i ) and ( ii ) above are contemplated under this Agre ement with respect to the IO Discovery Program Anti bodies as of the A&R Agreement Effective Date